Guardant Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Guardant Health, Inc. on June 4, 2020, reporting events occurring on June 1, 2020. The filing details an underwritten public offering of the Company's common stock.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or debt levels. Instead, it reports the following transaction specifics:
- Total Shares Offered: 11,500,000 shares of Common Stock.
- Offering Price: $84.00 per share.
- Primary Shares (Company): 3,750,000 shares issued and sold by Guardant Health.
- Secondary Shares (Selling Stockholder): 7,750,000 shares sold by SVF Bluebird (Cayman) Limited.
- Underwriter: J.P. Morgan Securities LLC.
- Over-Allotment Option: The Underwriter has a 30-day option to purchase up to 1,725,000 additional shares (562,500 from the Company and 1,162,500 from the Selling Stockholder).
Material Changes and Proceeds
The Company intends to use the net proceeds from the sale of Primary Shares for general corporate purposes, including working capital, sales and marketing activities, general and administrative matters, and capital expenditures. The Company will not receive any proceeds from the sale of Secondary Shares by the Selling Stockholder.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard legal disclaimers regarding the Underwriting Agreement. The agreement includes customary representations, warranties, covenants, and indemnification obligations.
Key Facts for Investor Verification
- Verify the final number of shares sold, including whether the over-allotment option was exercised.
- Confirm the actual net proceeds received by the Company after deducting underwriting discounts and commissions.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific covenants and indemnification terms.
- Monitor the dilution impact of the 3,750,000 Primary Shares issued by the Company.